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Abstract
Background: Human immunodeficiency virus (HIV) infection that persists despite antiretroviral therapy (ART) is a daunting
problem. Given the limited evidence that resting CD4+ T cell infection (RCI) is affected by the histone deacetylase (HDAC)
inhibitor valproic acid (VPA), we measured the stability of RCI and residual viremia in patients who added VPA with or
without raltegravir (RAL), or enfuvirtide (ENF) with or without VPA, to standard ART.
Methods: Patients with plasma HIV RNA,50 c/mL added sustained-release VPA (Depakote ERH) twice daily, RAL 400 mg
twice daily, or ENF 90 mcg twice daily. Change in RCI was measured by outgrowth assays. Low-level viremia was
quantitated by single-copy plasma HIV RNA assay (SCA).
Results: In three patients on standard ART a depletion of RCI was observed after 16 weeks of VPA, but this effect waned
over up to 96 weeks of further VPA. In two patients ENF added to stable ART had no effect on RCI. Simultaneous
intensification with ENF and addition of VPA had no effect on RCI frequency in one patient, and resulted in a 46% decline in
a second. No significant depletion of RCI (.50%) was seen in six volunteers after the addition of RAL and VPA. In 4 of the 6
patients this lack of effect might be attributed to intermittent viremia, low VPA levels, or intermittent study therapy
adherence. Overall, there was no effect of the addition of RAL or ENF on low-level viremia measured by SCA.
Conclusions: The prospective addition of VPA and RAL, VPA and ENF, or ENF failed to progressively reduce the frequency of
RCI, or ablate intermittent and low-level viremia. New approaches such as more potent HDAC inhibition, alone or in
combination with intensified ART or other agents that may disrupt proviral latency must be pursued.
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Introduction
Given the costs and difficulties in maintaining suppression of
viremia in the HIV-infected patients for decades, and the
challenges that face effective prevention of HIV infection, interest
has reawakened in interventions that might eradicate HIV
infection [1]. Currently, two challenges to the eradication of
infection are apparent: the persistence of latent infection, and the
persistent expression of low levels of virions from cells infected
prior to ART initiation. Clearance of HIV infection will almost
certainly require a multimodal approach that includes potent
suppression of HIV replication, therapies that reach all compart-
ments of residual HIV expression, and depletion of any reservoirs
of persistent, quiescent proviral infection. Reagents that selectively
induce the expression of quiescent proviral genomes but have
limited effects on host cell activation and susceptibility to infection
might allow outgrowth of latent HIV, and avoid the pitfalls of
global T cell activation [2,3].
Histone deacetylase (HDAC) is a critical regulator of HIV
latency [4], and in ex vivo assays HDAC inhibition leads to HIV
outgrowth from the resting CD4+ T-cells of aviremic patients [3].
In one small pilot study RCI was depleted when intensified ART
was given in combination with generic VPA, an anticonvulsant
and non-selective HDAC inhibitor [5]. However, little effect was
seen in two observational studies and one prospective trial in
which VPA was given without intensified ART [6–8].
In this prospective trial [8] a decrease in RCI was observed in
only 4 of the 11 patients. To extend these observations, we
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on standard ART after prolonged treatment with sustained-release
VPA and ART, and after intensified of ART by an agent acting
via a novel mechanism of action, entry inhibition or integrase
inhibition.
Methods
HIV-infected volunteers receiving stable ART with plasma
HIV-1 RNA,50 copies/ml and a CD4 count of .300/ml for at
least 6 months were studied. 3 HIV-infected males stably
suppressed on ART and previously treated with VPA (patients
1–3, as reported in ref. 8) in whom a significant decline in RCI was
measured after 16 weeks of VPA agreed to further study on
treatment with VPA. As reported [8], leukapheresis was performed
on two occasions (day 249 to 227 and day 0) prior to, and after
12 and 16 weeks of protocol therapy with the sustained-release
formulation of VPA (Depakote ERH). Patients 1–3 had a depletion
of RCI measured at weeks 12–16. As per protocol, VPA therapy
was continued past week 16 and repeat studies were planned at
weeks 48 and 96. Patient 3 was assessed at week 32, as he declared
his intention to leave the study after 48 weeks.
2 HIV-infected males stably suppressed on ART in whom no
effect of VPA was measured (patients 6 and 9, as reported in ref. 8)
agreed to intensify baseline ART with ENF. When RCI was
unchanged after ENF, patients 6 agreed to later intensify baseline
ART with ENF and VPA simultaneously. One newly enrolled
HIV-infected male stably suppressed on ART without previously
VPA exposure (patient 12) simultaneously added VPA and ENF to
baseline ART. As previously reported, patients 6 and 9 stopped
VPA when no decline of RCI was measured, but continued
baseline ART [8]. As per protocol, an additional RCI measure-
ment was made at study re-entry, before initiation of ENF 90 mcg
twice daily. Again patients stopped ENF when no decline of RCI
was measured, but continued baseline ART [8]. Patients 6 later
agreed to re-enter study, simultaneously adding VPA and ENF to
baseline ART. Patient 12 initiated study therapy with VPA and
ENF, but used the generic immediate-release formulation of VPA.
In a parallel study, seven HIV-infected males, stably suppressed
on ART (patients 13–18) enrolled to study the effect of the receipt
of VPA and RAL. Baseline ART included nucleoside RT
inhibitors and protease inhibitors (7 patients), or non-nucleoside
RT inhibitors (5 patients). CD4 cell counts at entry ranged from
320 to 1242 cells/ml (17–42%). Study therapy for this parallel
protocol included RAL 400 mg twice daily and VPA (Depakote
ERH) 500–750 mg bid for patients 13–18.
Enrollment criteria for both protocols have been described [8].
All patients provided written informed consent, and the study was
approved by the University of North Carolina Office of Human
Research Ethics Institutional Review Board.
Lymphocytes were obtained by continuous-flow leukapheresis.
Isolation of resting CD4+ T cells, recovery and quantification of
replication competent virus was performed as described, with
inter-assay variance of 0.3 log [8]. By protocol, changes in RCI of
more than 50% were deemed significant. Flow cytometry analysis
was performed on lymphocytes isolated at leukapheresis as
described [5] to verify purity of resting CD4+ T cell isolation.
Plasma HIV-1 RNA concentrations were measured by Roche
Amplicor (Roche Molecular Systems, Branchburg, NJ) with an
assay detection limit of 50 copies/ml. To accurately measure the
extent of low-level viremia, an ultra-sensitive, quantitative real-
time, RT-PCR single copy assay (SCA) capable of detecting and
quantifying plasma HIV-1 RNA to a limit of detection of 1 copy
per ml was performed [9]. SCA was performed on plasma samples
collected at the screening visit, at 27–49 days before the start of
protocol therapy, on the day 0 and weeks 1, 2, 4, 8, 12 and 16 after
the start of protocol therapy.
Results
Overall, VPA therapy was generally well tolerated, with only
minor or transient adverse events not clearly related to VPA. VPA
levels were infrequently above 60 mcg/ml. RAL was well tolerated
without adverse events. ENF was well tolerated, with minor,
transient injection site reaction in one patient. No significant
adverse effects (greater than ACTG Grade II) were noted in any
patients.
Patients 1–3 were found to have a .50% depletion of RCI on
two resting cell assays at week 12 and 16 of VPA therapy in a study
reported previously [ref. 8]. They agreed to extended VPA therapy
for re-evaluation at weeks 48 and 96. Despite continuous ART and
VPA, the depletion of RCI seen at week 16 regressed to baseline at
48 and 96 weeks (Table 1). SCA measurements generally correlated
with concurrent Amplicor results (Table 1). Intermittent viremia
was detected in patient 2 by Amplicor assay, but never on days
when SCA was measured. In patients 1–3 SCA viremia was rarely
.1 copy/ml. Total VPA levels were measured near trough, prior to
daily dosing, and ranged from undetectable to 82 mcg/ml.
Patients 6 and 9 in the same prior study [8] had no decline RCI
after 16 weeks of VPA. Nine and six months (respectively) after
VPA discontinuation, these patients intensified continuous ART
with the addition of ENF. 16 weeks of ENF had no effect on the
frequency of RCI (Table 1). In patient 9 but not patient 6,
intermittent viremia of .50 copies/ml by Amplicor assay was
observed. In this patient SCA was routinely positive at 2–24
copies/ml. These results appear consistent with variation in PCR-
based detection of stable low-level viremia, as described in a
longitudinal study [10].
Four months later patient 6, in whom RCI had been unaffected
by the addition of either VPA or ENF, agreed to undergo
simultaneous intensification with ENF and the reinitiation of VPA.
After 16 weeks of ART, VPA, and ENF, RCI remained low but
stable. VPA levels were adequate, and SCA stably ,1 copy/ml.
The use of the sustained-release formulation of VPA (Depakote
ERH) in these patients and those previously described [8] could
have resulted in a blunting of peak VPA levels needed for sufficient
HDAC inhibition in vivo. Therefore in an additional volunteer
(patient 12) naı ¨ve to VPA and ENF, we studied the effect of
simultaneous ENF intensification and generic VPA twice daily.
SCA was stably ,1 copy/ml, and VPA levels adequate, but we
discovered the patient had not taken 20–30% of study medication
at the end of the study period. Nevertheless, we observe a 46%
decline in RCI, a trend that failed to achieve our pre-established
criterion of a significant decline (.50%).
Patients 13–18, stably suppressed on ART, intensified ART
with the addition of 400 mg RAL twice daily and simultaneously
added VPA. Surprisingly, despite RAL intensification, patients 13,
14, and 15 had episodic viremia detected by Amplicor. Patients 13
and 15 had four episodes of detectable viremia by Amplicor assay,
while patient 14 was .50 copies on one occasion. VPA dose was
increased to 1500 mg/day in patients 15 and 17 for trough levels
consistently below 40 mcg/ml; levels of .50 mcg/ml were then
measured in patient 17, but not in patient 15. In patients 13, 14,
and 15, VPA levels were suboptimal, and patients 13 and 14 were
unwilling to escalate the dose of drug. Patient 14 missed at least a
week of study drug while traveling. None of patients 13–18 had
significant declines (.50%) in RCI. Overall, the addition of RAL
or ENF had no effect on viremia measured by SCA.
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In an initial study of the effect of 16 weeks of VPA prospectively
added to stable ART [8], RCI declined more than 50% in 4 of 11
study subjects. While this decline might represent assay variation,
it is important to note that an increase of RCI of more than 50% was
not seen in any subjects. As assay variation is expected to be
bimodal, this suggests the declines observed were biological.
Further, we have not observed a significant (.50%) upward
fluctuation of the RCI assay in any of the 22 patients we have
intensively studied [5,8, this report], except for subsequent assays
in patients 1, 2, and 3 following the .50% decline of RCI.
In this follow-up study, depletion of RCI was not sustained in
three patients studied over 48–96 weeks. It is therefore likely that
the initial decline of RCI and its eventual return to baseline
represents a biological event, rather than an assay artifact. A
mechanistic hypothesis to explain the transient decline in RCI
observed is that a population of latently HIV-infected cells are
affected by VPA exposure, but that homeostatic forces later restore
the size of the infected resting cell pool, as recently suggested by
Chomont and colleagues [11].
Low-level viral expression as measured by SCA was not
significantly diminished by VPA therapy in combination with
either ENF or RAL, or by ENF alone. ENF intensification has
recently been reported to have no effect on RCI, measured by
similar outgrowth [12]. Just as the intensification of ART by
protease inhibitors or RAL has not been observed to diminish
viremia measured by SCA [13,14], SCA was little affected by the
addition of VPA and RAL, VPA and ENF, or ENF alone.
Anecdotally, it is of interest to note that the level of residual
viremia appears to be related to the frequency of RCI. Given the
small sample size this can only be a preliminary observation, but is
consistent with the hypothesis that residual viremia originates from
persistently infected, long-lived T cells.
These findings provide several important insights for future
study of persistent HIV infection, and approaches to attack it.
Despite a sound scientific rationale for the testing of HDAC
inhibitors, only a single weak inhibitor, VPA, has been tested, and
only in a handful of patients. Furthermore, since 2005 VPA
donated for research use has been in a sustained-release
formulation, designed to blunt the exposure of patients to higher
peak serum levels of VPA. Future studies of HDAC inhibitors may
seek to maximize peak drug exposure levels and measure
biological markers such as acetylation of nucleosomal histone via
chromatin immunoprecipitation assays. One of the patients
reported herein (patient 12) was treated with generic VPA, with
a modest depletion of RCI that did not achieve the pre-
determined standard for significance.
Further, many patients had persistent or intermittent viremia
detected by standard Amplicor assay or by SCA. Such viremia
may blunt the ability to deplete RCI or to measure a depletion of
RCI. The persistence of this viremia despite novel ART highlights
a second significant obstacle to the eradication of HIV infection.
Depletion of RCI in the majority of HIV-infected patients with
stable suppression of viremia is an unrealized goal. Vorinostat, a
more potent HDAC inhibitor, can induce expression of latent
HIV [15,16] and HDAC inhibitors selective for the HDAC
isoforms most relevant to HIV regulation may be more efficacious
Table 1. Effect of VPA and intensified ART on resting cell infection and low-level viremia.
Patient Infected Resting CD4+ Cells per Billion*
Mean VPA
(mcg/ml)
Amplicor HIV RNA
copies/ml
Median HIV SCA**
(copies/ml)
baseline ART Weeks of ART & VPA
16 32 48 96
1 187 90 n.d. 170 219 44 (33–57) ,50 (n=10) ,1( ,1t o1 ;n=9 )
2 52 22 n.d. 82 96 53 (40–74) ,50 (n=9) and 56, 100 ,1( n=4 )
3 70 22 57 73 n.d.1 50 (,12–82) ,50 (n=8) ,1( n=4 )
ART ART & ENF616 wks
9 4254 4177 n.a. ,50 (n=6) and 75 13 (2 to 24; n=6)
6 59 116 n.a. ,50 (n=8) ,1( n=6 )
ART ART & ENF & VPA616 wks
6 109 127 61.4 (23–83) ,50 (n=6) ,1( ,1t o1 ;n=9 )
12 175 95 68{{ (55–90) ,50 (n=7) ,1( ,1; n=5)
ART ART & RAL & VPA616 wks
13 500 340 45{ (24–64) ,50 (n=12) and 118, 75, 73, 90 9 (2–24; n=11)
14 210 250{{ 36{ (20–60) ,50 (n=13) and 102 1 (,1–18; n=12)
15 410 600 42 (23–51) ,50 (n=10) and 60, 73, 98, 192 3 (,1–8; n=5)
16 400 440 59 (46–75) ,50 (n=13) 1 (,1t o7 ;n=1 3 )
17 27 33 70 (62–79) ,50 (n=14) ,1( ,1 to 35; n=12)
18 620 650 77 (50–93) ,50 (n=12) ,1( ,1 to 1.8; n=11)
*All results represent pooled assays at entry/week 24, and week 12/16. Baseline ART assays for patients 6, 9, and 12 represent pooled assays from entry/week 24a n d2
prior time points. Weeks 32, 48, 96 are assays from only those time points.
**Simultaneous Amplicor assays at all SCA time points were ,50 copies, except for patient 3 at day of study entry when Amplicor=58 and SCA.1000.
{Declined VPA dose escalation.
{{Intermittent non-adherence to study medication.
1Early study discontinuation.
doi:10.1371/journal.pone.0009390.t001
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that affect both histone acetylation and DNA/histone methylation,
or NF-kB signaling and histone acetylation might be necessary to
sufficiently perturb latent HIV infection [4,19,20]. Finally,
additional approaches may be needed to ablate low-level viremia.
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